WO1999018920A1 - A new powerful cosmetic or pharmaceutical composition - Google Patents
A new powerful cosmetic or pharmaceutical composition Download PDFInfo
- Publication number
- WO1999018920A1 WO1999018920A1 PCT/US1998/021794 US9821794W WO9918920A1 WO 1999018920 A1 WO1999018920 A1 WO 1999018920A1 US 9821794 W US9821794 W US 9821794W WO 9918920 A1 WO9918920 A1 WO 9918920A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- skin
- composition
- crude extract
- scalp
- wound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/37—Digestive system
- A61K35/39—Pancreas; Islets of Langerhans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/981—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/02—Preparations for cleaning the hair
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/007—Preparations for dry skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/006—Antidandruff preparations
Definitions
- the present invention relates to a crude extract (use extract for following) of animal pancreas, specifically to such extract which is used as a new, powerful, multi-function, cosmetic or pharmaceutical composition.
- Pancreas has both endocrine and exocrine functions, .and therefore, contains many biological active substances such as insulin, glucagon, somatostatin, pancreatic polypeptide, kallikrein, and p.ancreafin, etc. Certain active substances of animal pancreas have recently been used as cosmetic ingredients or ingredients of accelerating wound healing. So far, it includes kallikrein, pancreatin, and insulin.
- Kallikrein is used as a vasodilator. It is reported to improve cell mitosis, wound healing and oxygen uptake, .and protect from UV radiation (Natalia Michalun et al.).
- Pancreatin contains several enzymes that give it proteolytic, amylolytic .and lipolytic activity. Pancreatin is used as a raw material in biological exfoliant to help remove cells from corneum layer (Natalia Michalun et al.).
- Insulin is used as an ingredient of accelerating wound healing in Lindenbaum's formulations (U.S. Pat. No. 5461030 and 5591709).
- pancreas pancreas
- the extract of animal pancreas is a mixture; it contains many biologic active substances and other substances. Its effect on skin and wound has also not been understood yet. Perhaps, it is due to that the extract of pancreas contains many digestive enzymes such as trypsin, chymotrypsin, elastase, lipase, and phospholipase (Chandrasoma, Underwood, and Isselbacher). These enzymes are also called as pancreatin. They digest accidentallyly normal tissue cells and result in their necrosis .and bleeding.
- trypsin and chymotrypsin can cause necrosis and hemorrhage
- elastase causes vascular injury and local hemorrhage
- lipase and phospholipase cause respectively local fat necrosis
- cell membrane injury Choandrasoma, and Isselbacher
- peptide hormones such as insulin and kallikrein
- their amounts in the extract are far less than that of digestive enzymes, because the most of pancreas tissue are to produce pancreatin (Underwood).
- the anticipated effect of the extract on skin and wound should be harmful or can even be considered dangerous, even though the extract also contains insulin and kallikrein, because the damages of digestive enzymes to pancreas and peripancreatic tissues in pancreatitis is under this condition with insulin and kallikrein too (Chandrasoma, Underwood, and Isselbacher).
- present invention has prepared an extract of animal pancreas, and topically applied it to human skin and wound. Surprising is that this extract does not damage any normal tissue cells and wound. Instead, it helps wound healing, improves tissue cell metabolism, promotes cell turnover, enhances skin quality, moisturizes skin, cleanses skin .and makes skin to have a silky smooth feeling. Although the extract peels part of stratum corneum, this effect is self-limited, and it does not digest all stratum corneum. In addition, it can also be used to treat many keratoses such as ichthyosis, psoriasis, seborrheic keratoses. acne, dandruff, callous skin, etc. All above beneficial effects are not anticipated, but they meet the requirement used as a multi-function, cosmetic and pharmaceutical composition. Objects:
- the objects of present invention is to provide a method of preparing the extract of animal pancreas; to use said extract to make a product of cosmetic or pharmaceutical for treating skin, scalp, wound or some other diseases; and to disclose new active compositions in said extract.
- pancreatin has not yet be used in house-using cosmetic and pharmaceutical products, because pancreatin has always been considered very harmful to tissue cells.
- its peeling function also is distinctive than Rawlings reference (U.S. Patent No. 5554366).
- Rawlings active composition is stratum corneum chymotrypsin-like enzyme, but the extract of the present invention does not comprise stratum corneum chymotrypsin-like enzyme.
- the present invention pertains to discovering a new, powerful, multi-function cosmetic or pharmaceutical composition for topical application to the skin or wound, and to a method of making this composition.
- animal pancreases and solvents can be used to prepare the extract of animal pancreas, but preferably, I use swine pancreas, alcohol, and water to do it.
- concentration of alcohol is higher than 60%, more preferably use 95% alcohol or much higher concentration.
- Fresh or deepfrozen animal pancreases are ground or chopped up and suspended, while stirring, in double volume of 95% alcohol.
- the mixture is extracted for about several hours to 24 hours, then the mixture is centrifuged for a short time at about 5,000 rpm. Collect supernatant, and do not contaminate solid substance.
- the supernatant can topically be applied to the skin for skin care purposes after diluted by a dilutant, it is irritant to skin because it comprises too much alcohol.
- above supematant is concentrated by using vacuum pump or simply by blowing air into the supernatant to evaporate alcohol, but is not dried because dried extract is difficult to be completely dissolved again.
- the supernatant is concentrated to about one-fourth of volume.
- 10 ml of the supematant is concentrated to about 2.5 ml by evaporating alcohol.
- This concentrated supematant is an extract of animal pancreas. It is a yellow liquid including a water phase and an oil phase; its pH value is between 6 and 7.
- swine pancreas 50 g of swine pancreas is ground .and suspended, while stirring, in 100 ml of 95% alcohol. The mixture is extracted at room temperature for about 12 hours, then is centrifuged for 10 minutes at 5,000 rpm. Transfer supematant into a fresh container, and do not contaminate any solid substances. About 90 ml of the supematant can be collected. Vacuum 90 ml of supematant until the volume is decreased to about 22 ml. Now the extract of animal pancreas is gained.
- the extract of animal pancreas is formulated with cosmetically or pharmaceutically acceptable ingredients into a variety of emulsions or solutions to satisfy some cosmetic or pharmaceutical needs.
- the composition comprises about 1 to 13% more preferably 1 to 3% by weight of the extract of animal pancreas.
- the extract of pancreas can also directly and topically be applied to skin or scalp without dilution and without formulating with other cosmetic and pharmaceutical ingredients. It can even be used at concentrated condition without damage to skin and scalp.
- the alcohol in the extract is irritant to wound of skin and scalp.
- the water phase and oil phase of the extract can separately be used, or separately used as a cosmetic and pharmaceutical composition to be formulated with other ingredients into varied products of cosmetic or pharmaceutical.
- the function is not as broad as the whole extract. For example, water phase has more function of peeling and cleansing, oil phase has more function of moisturizing, healing wound, improving metabolism, and emollient.
- the extract can be heated to inactivate some active compositions sensitive to temperature, and to keep some compositions insensitive to temperature for particular use.
- the function of silky smooth feeling and peeling is kept by means of heating the extract, because the composition of providing these functions in the extract is insensitive to temperature.
- the extract in order to have a more specific function, can further be processed by adjusting pH, salting-out, dialyzing, crystallizing, chromatographing, or electrophoresis etc. to eliminate some unwanted compositions. For example, the decrease of pH value will lead to precipitation of some compositions and decrease of peeling function, and the increase of pH value will lead to decrease of reparative function.
- pancreatin separated by means of above methods can safely and self-limited peel stratum comeum without damage to normal tissue cells. Further purified trypsin .and chymotrypsin can also be used to peel stratum comeum.
- the pancreatin, trypsin and chymotrypsin can be used to treat many keratoses such as ichthyosis, psoriasis, seborrheic keratoses, acne, dandruff, callous skin, etc.
- the extract of animal pancreas comprises many active compositions such as insulin, glucagon, somatostatin, pancreatic polypeptide, kallikrein, elastase, pancreatin, fat, bile, and some unknown active compositions. Some of them are mutually antagonistic and some cooperative in function.
- active compositions such as insulin, glucagon, somatostatin, pancreatic polypeptide, kallikrein, elastase, pancreatin, fat, bile, and some unknown active compositions.
- pancreatin of the extract can digest skin tissue structure.
- the structure is destroyed; the functions beneficial to tissue cells can not be established. Therefore, the effect mechanism of animal pancreas extract can probably be inferred only by the result of experiments and practices. The following is the possible interpretations of some effect mechanisms of the extract.
- the insulin is an anabolic hormone, and therefore it provides a function of accelerating wound healing and a function of enhancing the quality of skin or scalp cells for the extract of animal pancreas.
- the kallikrein is a vasodilator which improves cell mitosis, wound healing and oxygen uptake, and protects from UV radiation (Natalia Michalun et al.), and therefore it provides a function of accelerating wound healing and a function of enhancing the quality of skin or scalp cells for the extract of animal pancreas.
- the pancreatin contains several enzymes such as amylases, lipases. nucleases, peptidases, trypsins, chymotrypsins, etc.
- the extract of animal pancreas also comprises some very important active compositions which have not been understood yet. Some of them provide a very powerful function of long-lasting moisturizing, some of them provide a very powerful function of making skin a long- lasting comfortable silky smooth feel, some of them provide a function of skin cleansing in combination with pancreatin, and some of them provide a function of accelerating wound healing in combination with kallikrein and insulin for the extract of animal pancreas.
- the compositions relative to moisturizing and silky smooth feel is stable in a wide range of pH value, and is serviceable to high temperature.
- the extract of animal pancreas has a very powerful function of long-lasting moisturizing, a very powerful function of making skin a long-lasting silky smooth feel, a powerful function of accelerating wound healing, a function of exfoliating comeum layer, a cleansing function, and a function of enhancing quality of skin or scalp cells, etc. Therefore, it can be used as a powerful, multi-function, cosmetic or pharmaceutical composition to formulate with cosmetically or pharmaceutically acceptable ingredients into emulsions or solutions to satisfy some cosmetic or pharmaceutical needs and provide much broader functions.
- composition according to the invention is intended primarily as the products for topical application to human skin or wound, for protecting normal skin from dry, restoring the skin to a healthy, hydrated, supple and soft condition, treating dry skin, alleviating dandruff, accelerating wound healing, making skin a comfortable silky smooth feel, cleansing skin, and enhancing the quality of skin and scalp cells, etc.
- a small quantity of the composition for example from 0.5 to 5 ml, is applied to area of the skin, scalp, or wound, it is then spread over and/or rubbed into the skin, scalp, or wound using the hand, fingers or a suitable device.
- the extract of the present invention is an excellently multifunction cosmetic or pharmaceutical composition. It can be used to protect normal skin from dry, restore the skin to a healthy, hydrated, supple and soft condition, treat dry skin, alleviate dandruff, provide a very comfortable silky smooth feel for the skin, cleanse skin, accelerate wound healing, enhance the quality of skin and scalp cells, etc. It can also be used in combination with many cosmetically or pharmaceutically acceptable ingredients to provide much broader functions. Furthermore, it has the additional advantages in that
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020007004092A KR20010031170A (en) | 1997-10-16 | 1998-10-15 | a new powerful cosmetic or pharmaceutical composition |
JP2000515558A JP2002509855A (en) | 1997-10-16 | 1998-10-15 | Composition for topical application to skin, scalp or wound and method for producing same |
CA002305507A CA2305507A1 (en) | 1997-10-16 | 1998-10-15 | A new powerful cosmetic or pharmaceutical composition |
EP98952317A EP1051142A4 (en) | 1997-10-16 | 1998-10-15 | A new powerful cosmetic or pharmaceutical composition |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US95193397A | 1997-10-16 | 1997-10-16 | |
US08/951,933 | 1997-10-16 | ||
US14892198A | 1998-09-04 | 1998-09-04 | |
US09/148,921 | 1998-09-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999018920A1 true WO1999018920A1 (en) | 1999-04-22 |
Family
ID=26846306
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1998/021794 WO1999018920A1 (en) | 1997-10-16 | 1998-10-15 | A new powerful cosmetic or pharmaceutical composition |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1051142A4 (en) |
JP (1) | JP2002509855A (en) |
KR (1) | KR20010031170A (en) |
CN (1) | CN1275897A (en) |
CA (1) | CA2305507A1 (en) |
WO (1) | WO1999018920A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7402571B2 (en) | 2000-07-31 | 2008-07-22 | Bar-Ilan University | Methods and pharmaceutical compositions for healing wounds |
US7638484B2 (en) | 2003-08-07 | 2009-12-29 | Healor Ltd. | Methods for accelerating wound healing by administration of adipokines |
WO2009155689A1 (en) * | 2008-06-24 | 2009-12-30 | Micropharma Limited | Nitric oxide device and method for wound healing, treatment of dermatological disorders and microbial infections |
US8093211B2 (en) | 2000-07-31 | 2012-01-10 | Bar-Ilan University | Methods and pharmaceutical compositions for healing wounds |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020119914A1 (en) * | 2000-12-26 | 2002-08-29 | Deguang Zhu | New uses of insulin and pancreatin |
US20080058282A1 (en) | 2005-08-30 | 2008-03-06 | Fallon Joan M | Use of lactulose in the treatment of autism |
US8658163B2 (en) | 2008-03-13 | 2014-02-25 | Curemark Llc | Compositions and use thereof for treating symptoms of preeclampsia |
US8084025B2 (en) | 2008-04-18 | 2011-12-27 | Curemark Llc | Method for the treatment of the symptoms of drug and alcohol addiction |
ES2732453T3 (en) | 2008-07-01 | 2019-11-22 | Curemark Llc | Methods and compositions for the treatment of symptoms of neurological and mental health disorders |
US9084784B2 (en) | 2009-01-06 | 2015-07-21 | Curelon Llc | Compositions and methods for the treatment or the prevention of E. coli infections and for the eradication or reduction of E. coli surfaces |
US9056050B2 (en) | 2009-04-13 | 2015-06-16 | Curemark Llc | Enzyme delivery systems and methods of preparation and use |
MX362974B (en) | 2011-04-21 | 2019-02-28 | Curemark Llc | Compounds for the treatment of neuropsychiatric disorders. |
CN107261126A (en) * | 2012-02-02 | 2017-10-20 | 加尔纳根有限责任公司 | Enzymatic compositions and its purposes for wound healing |
JP6244578B2 (en) * | 2012-03-29 | 2017-12-13 | 太邦株式会社 | Water-soluble royal jelly and method for producing the same |
US10350278B2 (en) | 2012-05-30 | 2019-07-16 | Curemark, Llc | Methods of treating Celiac disease |
CN103405751B (en) * | 2013-08-22 | 2015-05-20 | 赵轩 | Composition with cell repairing function and preparation method and application thereof |
CN105605329A (en) * | 2015-10-09 | 2016-05-25 | 武汉武船机电设备有限责任公司 | Flange connecting cabin penetration pipe fitting |
US11541009B2 (en) | 2020-09-10 | 2023-01-03 | Curemark, Llc | Methods of prophylaxis of coronavirus infection and treatment of coronaviruses |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4071410A (en) * | 1975-11-08 | 1978-01-31 | Eisai Co., Ltd. | Process for preparation of pancreatic elastase |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR1039M (en) * | 1961-04-04 | 1962-01-02 | Max Joseph Pierre | Ribonuclease-based medicine for the treatment of psoriasis and other dermatoses. |
US3267006A (en) * | 1962-04-20 | 1966-08-16 | Armour Pharma | Pancreatic collagenase and preparation of same |
JPS55104206A (en) * | 1979-02-05 | 1980-08-09 | Rooman Kogyo:Kk | Cosmetic containing enzyme |
CA1168980A (en) * | 1980-04-17 | 1984-06-12 | Rolf Schafer | Wound healing compositions |
WO1984002846A1 (en) * | 1983-01-21 | 1984-08-02 | Advanced Drug Tech | Enzyme ointment |
JPS6064909A (en) * | 1983-09-20 | 1985-04-13 | Shiseido Co Ltd | Cosmetic |
JPS6191133A (en) * | 1984-10-11 | 1986-05-09 | Eisai Co Ltd | Agent for improving dermatic metabolism |
US5591709A (en) * | 1991-08-30 | 1997-01-07 | Life Medical Sciences, Inc. | Compositions and methods for treating wounds |
CN1106254A (en) * | 1994-01-24 | 1995-08-09 | 徐德茂 | Pancreatinum skin protecting and face-care cosmetics and its prodn. method |
-
1998
- 1998-10-15 EP EP98952317A patent/EP1051142A4/en not_active Withdrawn
- 1998-10-15 CN CN98810221A patent/CN1275897A/en active Pending
- 1998-10-15 JP JP2000515558A patent/JP2002509855A/en active Pending
- 1998-10-15 CA CA002305507A patent/CA2305507A1/en not_active Abandoned
- 1998-10-15 KR KR1020007004092A patent/KR20010031170A/en not_active Application Discontinuation
- 1998-10-15 WO PCT/US1998/021794 patent/WO1999018920A1/en not_active Application Discontinuation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4071410A (en) * | 1975-11-08 | 1978-01-31 | Eisai Co., Ltd. | Process for preparation of pancreatic elastase |
Non-Patent Citations (1)
Title |
---|
See also references of EP1051142A4 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7402571B2 (en) | 2000-07-31 | 2008-07-22 | Bar-Ilan University | Methods and pharmaceutical compositions for healing wounds |
US8093211B2 (en) | 2000-07-31 | 2012-01-10 | Bar-Ilan University | Methods and pharmaceutical compositions for healing wounds |
US7638484B2 (en) | 2003-08-07 | 2009-12-29 | Healor Ltd. | Methods for accelerating wound healing by administration of adipokines |
WO2009155689A1 (en) * | 2008-06-24 | 2009-12-30 | Micropharma Limited | Nitric oxide device and method for wound healing, treatment of dermatological disorders and microbial infections |
Also Published As
Publication number | Publication date |
---|---|
CA2305507A1 (en) | 1999-04-22 |
CN1275897A (en) | 2000-12-06 |
EP1051142A4 (en) | 2002-01-30 |
JP2002509855A (en) | 2002-04-02 |
KR20010031170A (en) | 2001-04-16 |
EP1051142A1 (en) | 2000-11-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1051142A1 (en) | A new powerful cosmetic or pharmaceutical composition | |
US20020119914A1 (en) | New uses of insulin and pancreatin | |
JP3513873B2 (en) | External preparation for skin | |
RU2169000C2 (en) | Use of iridaceae extract, composition containing thereof and method of cosmetic treatment | |
US20060013845A1 (en) | Oxygenated personal care products | |
JPH08505630A (en) | Pharmaceutical and skin cosmetic compositions containing equine colostrum | |
EP1825845A1 (en) | Cosmetic herbal compositions | |
JP3576200B2 (en) | Whitening cosmetics | |
CN100558340C (en) | Cucurbitaceae oil is used to suppress the active application of 5 | |
US6096327A (en) | Cosmetic compositions containing human type serine protease inhibitors for revitalizing the skin | |
CN110151630A (en) | A kind of whitening and skin-protecting composition | |
JP2008143784A (en) | Cell growth promoter | |
DE10033717A1 (en) | Cosmetic and dermatological preparation for removing sebum | |
JP2631711B2 (en) | Cosmetics | |
JP3280903B2 (en) | External preparation for skin | |
JP2002308750A (en) | Skin care preparation | |
US20080166335A1 (en) | Slimming Cosmetic Composition Comprising a Metalloproteinase as an Active Agent | |
WO1994002118A1 (en) | Skin regenerating cosmetic composition | |
JPH10251133A (en) | Preparation for external use for skin | |
JPH0899819A (en) | Anti-fungus pharmaceutical preparation for making-up and dermatology | |
CN115350109A (en) | Cosmetic composition for skin whitening or skin wrinkle improvement and method for producing the same | |
EP1586336A1 (en) | Compositions containing copper salts and soy products | |
CA2312075A1 (en) | Cosmetic compositions containing human type serine protease inhibitors | |
JP3974003B2 (en) | Hair growth material and external preparation for skin containing the same | |
KR101816816B1 (en) | Compositions for Angiogenesis, Skin Whitening and Anti-inflammatory Containing Lonicerae Flos Extract |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 98810221.8 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA CN JP KR |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2305507 Country of ref document: CA Ref document number: 2305507 Country of ref document: CA Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2000 515558 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020007004092 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998952317 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1998952317 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020007004092 Country of ref document: KR |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1998952317 Country of ref document: EP |
|
WWR | Wipo information: refused in national office |
Ref document number: 1020007004092 Country of ref document: KR |